Condition: Elevated Blood Pressure · Hypertension · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacokinetics, and pharmacodynamics of HJB647 following single dose administration in Japanese healthy participants with elevated blood pressure and multiple dose administration with up titration in Japanese patients with hypertension, to support future clinical development of HJB647
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +81337978748 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Sumida Ku, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07644364